WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classificati n 6: A61K 31/00, 31/42, 31/165, 31/415, 31/44, 31/41, 31/19, 31/38, 31/35, 31/045, 31/365, 31/05

A3

(11) International Publication Number:

WO 97/11690

(43) International Publication Date:

3 April 1997 (03.04.97)

(21) International Application Number:

PCT/US96/15435

(22) International Filing Date:

25 September 1996 (25.09.96)

(30) Priority Data:

60/004,626 08/672,215 29 September 1995 (29.09.95) US US

25 June 1996 (25.06.96)

Published

With international search report.

GR, IE, IT, LU, MC, NL, PT, SE).

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71) Applicant: MICROCIDE PHARMACEUTICALS, INC. [US/US]; 850 Maude Avenue, Mountain View, CA 94043

(72) Inventors: BAO, Ying; 1291 Vincente Drive #248, Sunnyvale, CA 94086 (US). BOGGS, Amy; 490 Sherwood Way #3, Menlo Park, CA 94025 (US). CONTAG, Pamela, R.; 6110 Bollinger Road, San Jose, CA 95129 (US). FEDERSPIEL, Nancy, A.; 1345 Altschul Avenue, Menlo Park, CA 94025 (US). HEBERT, Alan; 450 8th Avenue, Menlo Park, CA 94025 (US). HECKER, Scott; 16387 Englewood Avenue, Las Gatos, CA 95032 (US). MALOUIN, Francois; 18400 Overlook Road, #6, Los Gatos, CA 95030 (US).

(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US).

(88) Date of publication of the international search rep rt: 12 September 1997 (12.09.97)

(81) Designated States: AU, CA, CU, DE, IL, JP, MX, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB,

(54) Title: INHIBITORS OF REGULATORY PATHWAYS

(57) Abstract

Methods are provided for screening for potential inhibitors of bacterial, or other microbial, global pathogenesis gene regulators and other gene regulators. Methods are also provided for treating microbial (e.g., bacterial) infections using such inhibitors. Also included are pharmaceutical compositions containing such inhibitors. The screening methods involve detecting whether the activity of a gl bal pathogenesis gene regulator is altered in the presence of a test compound.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
ΑU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JР	Japan	PT	Portugal .
BR	Brazi)	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	ΚZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Larvia	TJ	Talikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	Prance	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K31/00 A61K3 A61K31/42 A61K31/165 A61K31/415 A61K31/44 A61K31/41 A61K31/19 A61K31/38 A61K31/35 A61K31/045 A61K31/365 A61K31/05 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X JOURNAL OF BACTERIOLOGY, 1-7,9, vol. 176, no. 13, July 1994, 11-18, pages 4168-4172, XP000645499 20,22, CHEUNG A L ET AL: "CLONING AND SEQUENCING 50,51, OF SARA OF STAPHYLOCOCCUS AUREUS, A GENE 79-81, REQUIRED FOR THE EXPRESSION OF AGR" 83,85-87 see the whole document X,P WO 96 10579 A (UNIV NEW YORK) 11 April 1-22 1996 see the whole document X WO 94 02586 A (AGRICULTURAL & FOOD RES 1 ; PARK SIMON FEARON (GB)) 3 February 1994 see page 2, line 6 - line 8 -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the 'A' document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document referring to an oral disclosure, use, exhibition or document is combined with one or more other such do other means nts, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "A" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 18 July 1997 3 1. 07. 9**7** Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL - 2220 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Trifilieff-Riolo, S

• 1

Inter mai Application No PCT/US 96/15435

		PCT/US 96/15435
	iation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	. Kelevant to claim No.
K,P	LV 10 915 B (BF ESSE SIA) 20 April 1996	1-23, 50-52, 79-87
	see page 7; table 1	
	JOURNAL OF BACTERIOLOGY, vol. 175, no. 24, December 1993, pages 7875-7879, XP000645497 HART M E ET AL: "THE EXTRACELLULAR PROTEIN REGULATOR (XPR) AFFECTS EXOPROTEIN AND AGR MRNA LEVELS IN STAPHYLOCOCCUS AUREUS" see the whole document	1-8, 11-19, 22,50, 51, 79-82, 85-87
(INFECTION AND IMMUNITY, vol. 60, no. 8, August 1992, pages 3381-3388, XP000645259 REGASSA L B ET AL: "GLUCOSE AND NONMAINTAINED PH DECREASE EXPRESSION OF THE ACCESSORY GENE REGULATOR (AGR) IN STAPHYLOCOCCUS AUREUS" see the whole document	1-7, 11-18, 22,50, 51, 79-81, 85-87
(CANADIAN JOURNAL OF MICROBIOLOGY, vol. 40, August 1994, pages 677-681, XP000645258 GIRAUDO A T ET AL: "CHARACTERIZATION OF A TN551-MUTANT OF STAPHYLOCOCCUS AUREUS DEFECTIVE IN THE PRODUCTION OF SEVERAL EXOPROTEINS" see the whole document	1-3,5,7, 10-14, 16,18, 21,22, 50,51, 79,80, 84,85
	PHYTOCHEMISTRY, vol. 36, no. 4, 1994, XP000645959 ULUBELEN A ET AL: "TERPENOIDS FROM SALVIA SCLAREA" see the whole document	23,24, 52,53
	P.N.A.S, vol. 90, 1993, pages 965-969, XP002035604 ROYCHOUDHURY ET AL: "inhibitors of 2-component signal transduction systems: inhibition of alginate gene activation in Pseudomonas aeruginosa" cited in the application see the whole document	88-90, 98,99
	PATENT ABSTRACTS OF JAPAN vol. 095, no. 007, 31 August 1995 & JP 07 089924 A (SHIRATORI SEIYAKU KK), 4 April 1995, see abstract	61,62
Ì	-/	

ETIERNATIONAL SEARCH REPURI

Inter onal Application No

2.0		PCT/US S	96/15435
C.(Continua Category *	ction) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages		I Belgman to the
	appropriate, of the relevant passages	•	Relevant to claim No.
	DE 31 08 067 A (BAYER AG) 16 September 1982 see page 19; example 3		61,62
	MED. PARAZITOL. PARAZIT. BOLEZNI, vol. 6, 1991, pages 52-53, XP002035605 MIKHAILITSYN ET AL: "search for new antiparasitic agents"		40,41
	see page 53; table 2		
		·	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Intr tional application No.

PCT/US 96/15435

Box I Observation of item I of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(2) for the following reasons:	
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 1-49 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.	
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
SEE NEXT PAGE	
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. X As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Noz.:	
Subjects 1 5 and 9 Please see next page for further information	
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.	

FURTHER INFORMATION CONTINUED FR M PCT/ISA/210

subject 1: claims 1 to 22 (all partially), 23, 24, 50-51 (both partially), 52, 53, 79-103 (all 24 partially): use of a compound of formula 1 or 1A to treat or prevent a bacterial infection, compositions comprising said compound, method of screening for such a compound, method of producing an antibacterial agent comprising this compound

subject 2: claims 1 to 22 (all partially), 25, 26, 27, 50-51 (both partially), 54, 55, 56, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 2 or 2A (as far as not comprised in subject 1)

subject 3: claims 1 to 22 (all partially), 28, 29, 50-51 (both partially), 57, 58, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 4 or 4A (as far as not comprised in subjects 1-2)

subject 4: claims 1 to 22 (all partially), 30, 31, 50-51 (both partially), 59, 60, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 5 or 5A (as far as not comprised in subjects 1-3)

subject 5: claims 1 to 22 (all partially), 32, 33, 50-51 (both partially), 61, 62, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 6 or 6A (as far as not comprised in subjects 1-4)

subject 6: claims 1 to 22 (all partially), 34, 35, 50-51 (both partially), 63, 64, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 7 or 7A (as far as not comprised in subjects 1-5)

subject 7: claims 1 to 22 (all partially), 36, 37, 50-51 (both partially), 65, 66, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 8 or 8A (as far as not comprised in subjects 1-6)

subject 8: claims 1 to 22 (all partially), 38, 39, 50-51 (both partially), 67, 68, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 9 or 9A (as far as not comprised in subjects 1-7)

subject 9: claims 1 to 22 (all partially), 40, 41, 50-51 (both partially), 69, 70, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 10 or 10A (as far as not comprised in subjects 1-8)

subject 10: claims 1 to 22 (all partially), 42, 43, 50-51 (both partially), 71, 72, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 11 or 11A (as far as not comprised in subjects 1-9)

subject 11: claims 1 to 22 (all partially), 44, 45, 50-51 (both partially), 73, 74, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 12 or 12A (as far as not comprised in subjects 1-10)

FURTHER INFORMATION C NTINUED FR M PCT/ISA/210

subject 12: claims 1 to 22 (all partially), 46, 47, 50-51 (both partially), 75, 76, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 13 or 13A (as far as not comprised in subjects 1-11)

subject 13: claims 1 to 22 (all partially), 48, 49, 50-51 (both partially), 77, 78, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 14 or 14A (as far as not comprised in subjects 1-12)

HILLERIVATIONAL GRANCH RELORI

Information on patent family members

Intel Onal Application No PCT/US 96/15435

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9610579 A	11-04-96	AU 3825995 A	26-04-96
WO 9402586 A	03-02-94	AU 4714493 A	14-02-94
LV 10915 B	20-04-96	NONE	
DE 3108067 A	16-09-82	EP 0059400 A JP 1594102 C JP 2019825 B JP 57158751 A	08-09-82 14-12-90 07-05-90 30-09-82



PCT

08/672,215

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
A61K 31/00, 31/42, 31/165, 31/415, 31/44,
31/41, 31/19, 31/38, 31/35, 31/045, 31/365,
31/05

(11) International Publication Number: WO 97/11690

(43) International Publication Date: 3 April 1997 (03.04.97)

US

(21) International Application Number: PCT/US96/15435

(22) International Filing Date: 25 September 1996 (25.09.96)

25 June 1996 (25.06.96)

(30) Priority Data: 60/004,626 29 September 1995 (29.09.95) US

(71) Applicant: MICROCIDE PHARMACEUTICALS, INC. [US/US]; 850 Maude Avenue, Mountain View, CA 94043

(72) Inventors: BAO, Ying; 1291 Vincente Drive #248, Sunnyvale, CA 94086 (US). BOGGS, Amy; 490 Sherwood Way #3, Menlo Park, CA 94025 (US). CONTAG, Pamela, R.; 6110 Bollinger Road, San Jose, CA 95129 (US). FEDERSPIEL, Nancy, A.; 1345 Altschul Avenue, Menlo Park, CA 94025 (US). HEBERT, Alan; 450 8th Avenue, Menlo Park, CA 94025 (US). HECKER, Scott; 16387 Englewood Avenue, Las Gatos, CA 95032 (US). MALOUIN, Francois; 18400 Overlook Road, #6, Los Gatos, CA 95030 (US).

(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US). (81) Designated States: AU, CA, CU, DE, IL, JP, MX, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report: 12 September 1997 (12.09.97)

(54) Title: INHIBITORS OF REGULATORY PATHWAYS

(57) Abstract

Methods are provided for screening for potential inhibitors of bacterial, or other microbial, global pathogenesis gene regulators and other gene regulators. Methods are also provided for treating microbial (e.g., bacterial) infections using such inhibitors. Also included are pharmaceutical compositions containing such inhibitors. The screening methods involve detecting whether the activity of a global pathogenesis gene regulator is altered in the presence of a test compound.

^{* (}Referred to in PCT Gazette No. 22/1997, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Groece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Paso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Îtaly	PL	Poland
BJ	Benin	JP.	Japan	PT	Portugal
BR	Brazil	KB	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakheian	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	170	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Letvia	T.J	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE.	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	Prance	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

Inter nal Application No PCT/US 96/15435

			PCT,	/US 96/15435
IPC 6	A61K31/41 A61K31/19 A61K A61K31/365 A61K31/05	31/38	•	A61K31/44 A61K31/045
	to International Patent Classification (IPC) or to both national S SEARCHED	classification	and IPC	
Minimum	documentation searched (classification system followed by cla	ssification sym	spois)	
IPC 6	A61K	-	·	
Documenta	tion searched other than minimum documentation to the exten	t that such do	cuments are included in t	he fields searched
Electronic	lata base consulted during the international search (name of di	ata base and, a	where practical, search ter	ms used)
	ENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of	the relevant p	ranter	Relevant to claim No.
X	JOURNAL OF BACTERIOLOGY, vol. 176, no. 13, July 1994, pages 4168-4172, XP000645499 CHEUNG A L ET AL: "CLONING AN OF SARA OF STAPHYLOCOCCUS AURE REQUIRED FOR THE EXPRESSION OF see the whole document	US. A G	NC I NG ENE	1-7,9, 11-18, 20,22, 50,51, 79-81, 83,85-87
X,P	WO 96 10579 A (UNIV NEW YORK) 1996 see the whole document	11 Apri	1	1-22
X	WO 94 02586 A (AGRICULTURAL & ;PARK SIMON FEARON (GB)) 3 Feb see page 2, line 6 - line 8	FOOD RES	5 994	1
	 	-/		
X Furth	er documents are listed in the continuation of box C.	X	Patent family members an	e listed in annex.
'A' document 'E' earlier de filing da 'L' document which is citation 'O' document other me document later than	t which may throw doubts on priority claim(s) or cited to establish the publication date of another or other special reason (as specified) I referring to an oral disclosure, use, exhibition or	"X" documents of the control of the	nonty date and not in con- to understand the principation ment of particular relevan- ot be considered novel or we an inventive step wher- ment of particular relevan- not be considered to involve ment in combined with on- it, such combination being a srt. ment member of the same	the document is taken alone ot; the claimed invention e an inventive step when the e or more other such docu- ; obvious to a person skilled patent family
		Date	of mailing of the internati	onal search report
	July 1997		3 1. 07.	97
lame and ma	iling address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Ripwijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		nzed officer Trifilieff-Ric	olo, S

Form PCT/ISA/210 (second sheet) (July 1992)

· 1

Inter mal Application No PCT/US 96/15435

PCT/US 96/15435				
(Continu	Relevant to claim No.			
Х,Р	LV 10 915 B (BF ESSE SIA) 20 April 1996	1-23, 50-52, 79-87		
	see page 7; table 1	/9-8/		
X	JOURNAL OF BACTERIOLOGY, vol. 175, no. 24, December 1993, pages 7875-7879, XP000645497 HART M E ET AL: "THE EXTRACELLULAR PROTEIN REGULATOR (XPR) AFFECTS EXOPROTEIN AND AGR MRNA LEVELS IN STAPHYLOCOCCUS AUREUS" see the whole document	1-8, 11-19, 22,50, 51, 79-82, 85-87		
	INFECTION AND IMMUNITY, vol. 60, no. 8, August 1992, pages 3381-3388, XP000645259 REGASSA L B ET AL: "GLUCOSE AND NONMAINTAINED PH DECREASE EXPRESSION OF THE ACCESSORY GENE REGULATOR (AGR) IN STAPHYLOCOCCUS AUREUS" see the whole document	1-7, 11-18, 22,50, 51, 79-81, 85-87		
(CANADIAN JOURNAL OF MICROBIOLOGY, vol. 40, August 1994, pages 677-681, XP000645258 GIRAUDO A T ET AL: "CHARACTERIZATION OF A TN551-MUTANT OF STAPHYLOCOCCUS AUREUS DEFECTIVE IN THE PRODUCTION OF SEVERAL EXOPROTEINS" see the whole document	1-3,5,7, 10-14, 16,18, 21,22, 50,51, 79,80, 84,85		
•	PHYTOCHEMISTRY, vol. 36, no. 4, 1994, XP000645959 ULUBELEN A ET AL: "TERPENOIDS FROM SALVIA SCLAREA" see the whole document	23,24, 52,53		
	P.N.A.S, vol. 90, 1993, pages 965-969, XP002035604 ROYCHOUDHURY ET AL: "inhibitors of 2-component signal transduction systems: inhibition of alginate gene activation in Pseudomonas aeruginosa" cited in the application see the whole document	88-90, 98,99		
	PATENT ABSTRACTS OF JAPAN vol. 095, no. 007, 31 August 1995 & JP 07 089924 A (SHIRATORI SEIYAKU KK), 4 April 1995, see abstract	61,62		

i

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Inte onal Application No PCT/US 96/15435

C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/05 90	CT/US 96/15435	
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
	and appopulation of the relevant passages	•	research to estim No.	
X	DE 31 08 067 A (BAYER AG) 16 September 1982 see page 19; example 3		61,62	
A	MED. PARAZITOL. PARAZIT. BOLEZNI, vol. 6, 1991, pages 52-53, XP002035605 MIKHAILITSYN ET AL: "search for new antiparasitic agents" see page 53; table 2		40,41	
	÷			
	·			
		·		
	·			
	,			
	:			
	(continuation of second sheet) (July 1992)			

1

Intrintional application No.

PCT/US 96/15435

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Int	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X 2	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 1-49 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Rex 11	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
SEE	E NEXT PAGE
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
,	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	Subjects 1 5 and 9 Please see next page for further information
4	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark o	The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FR M PCT/ISA/210

subject 1: claims 1 to 22 (all partially), 23, 24, 50-51 (both partially), 52, 53, 79-103 (all 24 partially): use of a compound of formula 1 or 1A to treat or prevent a bacterial infection, compositions comprising said compound, method of screening for such a compound, method of producing an antibacterial agent comprising this compound

subject 2: claims 1 to 22 (all partially), 25, 26, 27, 50-51 (both partially), 54, 55, 56, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 2 or 2A (as far as not comprised in subject 1)

subject 3: claims 1 to 22 (all partially), 28, 29, 50-51 (both partially), 57, 58, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 4 or 4A (as far as not comprised in subjects 1-2)

subject 4: claims 1 to 22 (all partially), 30, 31, 50-51 (both partially), 59, 60, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 5 or 5A (as far as not comprised in subjects 1-3)

subject 5: claims 1 to 22 (all partially), 32, 33, 50-51 (both partially), 61, 62, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 6 or 6A (as far as not comprised in subjects 1-4)

subject 6: claims 1 to 22 (all partially), 34, 35, 50-51 (both partially), 63, 64, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 7 or 7A (as far as not comprised in subjects 1-5)

subject 7: claims 1 to 22 (all partially), 36, 37, 50-51 (both partially), 65, 66, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 8 or 8A (as far as not comprised in subjects 1-6)

subject 8: claims 1 to 22 (all partially), 38, 39, 50-51 (both partially), 67, 68, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 9 or 9A (as far as not comprised in subjects 1-7)

subject 9: claims 1 to 22 (all partially), 40, 41, 50-51 (both partially), 69, 70, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 10 or 10A (as far as not comprised in subjects 1-8)

subject 10: claims 1 to 22 (all partially), 42, 43, 50-51 (both partially), 71, 72, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 11 or 11A (as far as not comprised in subjects 1-9)

subject 11: claims 1 to 22 (all partially), 44, 45, 50-51 (both partially), 73, 74, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 12 or 12A (as far as not comprised in subjects 1-10)

FURTHER INFORMATION CONTINUED FR M PCT/ISA/210

<u>subject 12</u>: claims 1 to 22 (all partially), 46, 47, 50-51 (both partially), 75, 76, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 13 or 13A (as far as not comprised in subjects 1-11)

subject 13: claims 1 to 22 (all partially), 48, 49, 50-51 (both partially), 77, 78, 79-103 (all 24 partially): use, composition, method of screening and of producing an antibacterial agent as in subject 1 but relating to a compound of formula 14 or 14A (as far as not comprised in subjects 1-12)

Information on patent family members

Inten onal Application No PCT/US 96/15435

			101/00 00/20100	
Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 9610579 A	11-04-96	AU 3825995 A	26-04-96	
WO 9402586 A	03-02-94	AU 4714493 A	14-02-94	
LV 10915 B	20-04-96	NONE		
DE 3108067 A	16-09-82	EP 0059400 A JP 1594102 C JP 2019825 B JP 57158751 A	08-09-82 14-12-90 07-05-90 30-09-82	

Form PCT/ISA/210 (patent family sames) (July 1992)